Barbara Sennino, PhD
Dr. Sennino is a seasoned expert in cancer immunotherapy, bringing over 15 years of experience from both academic institutions and biotechnology companies. Before joining 3T, she served as Vice President of Immunotherapy at Turnstone Biologics, leading the preclinical development of targeted tumor-infiltrating lymphocyte (TIL) programs. She has also held leadership roles at PACT Pharma, focusing on next-generation T cell receptor (TCR) therapies for solid tumors, and contributed to Five Prime Therapeutics and Bavarian Nordic after completing her postdoctoral fellowship at the University of California, San Francisco. Dr. Sennino has published numerous articles in leading medical journals and holds several patents related to T cell therapies. She earned her M.Sc. in Biology from Milan, Italy, and her Ph.D. in Biomedical Sciences from Brescia, Italy.
